We operate in three business segments: Human Health (previously named "Pharmaceutical"), Consumer Healthcare and Animal Health.

We also operate several other businesses, including the manufacture of empty soft-gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. Due to the size of these businesses, they are grouped in and their results and assets are included in the "Corporate/Other" category of our segment information.

Our Human Health business is the largest pharmaceutical business in the world. This segment includes treatments for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders and allergies. . We recorded product sales of more than $1 billion for each of ten pharmaceutical products in 2004. Those ten products - Lipitor, Norvasc, Zoloft, Celebrex, Neurontin, Zithromax, Viagra, Zyrtec, Bextra and Xalatan - represented 69% of Human Health revenues in 2004. A table captioned Revenues - Major Human Health Products in our 2004 Financial Report is incorporated by reference. Consumer Healthcare Segment

Our Consumer Healthcare business is one of the largest in the world. We market many of the world's best-known OTC medications for oral care, upper respiratory health, tobacco dependence, gastrointestinal health, skin care, eye care and hair growth.

Our Animal Health business is the largest in the world. We discover, develop and sell products for the prevention and treatment of diseases in livestock and companion animals. In 2004, Animal Health revenues increased 22%, to $2.0 billion, due to strong performances by key in-line brands, significant product launches including Draxxin and Excede for respiratory disease in cattle and swine, strong growth in sales of Rimadyl, Revolution and Clavamox for companion animals, the favorable impact of foreign exchange and the inclusion of Pharmacia product revenues for a full year. Revenues from this segment contributed 3.7% of our total revenues in 2004, 3.6% of total revenues in 2003 and 3.5% of total revenues in 2002.